Background: Additional limus stent (Sirolimus-eluting stent [SES] and Everolimuseluting stent [EES]) on SES-ISR lesions has been a matter of controversy. This prompted us to assess the clinical outcomes of additional limus stent in patients presenting with SES-ISR comparing with balloon angioplasty. Methods: Patients with SES-ISR undergoing repeat target lesion revascularization (TLR) were included. We grouped the patients according to the treatment into EES, SES, and balloon angioplasty (BA) groups. The end points were a comparison of major adverse cardiac events (MACE) composed by all-cause mortality, myocardial infarction (MI) and TLR, the incidence of definite stent thrombosis (ST), and the adjusted determinants of MACE at 1 year derived by Cox multivariate analysis. Results: Overall 308 patients [EES (n¼41), SES (n¼102) and BA (n¼165)] were treated for SES-ISR. The baseline patient characteristics were similar between 3 groups. The incidence of MACE in the EES, SES and BA groups were 14.6%, 18%, 20%; respectively (3 way p¼0.72). The incidence of ST was 0% in all the groups. The adjusted determinants of MACE at 1 year were acute MI as SES-ISR presentation, number of treated lesions, diabetes mellitus, past MI history. (Table) Conclusion: The incidence of MACE in patients with SES-ISR was not statistically different between an additional limus stent implantation (EES or SES) and balloon angioplasty. Additionally, MI as SES-ISR presentation was the strongest determinant of MACE at 1 year.

